共查询到20条相似文献,搜索用时 311 毫秒
1.
2.
3.
4.
5.
6.
7.
8.
9.
Molecular regulation of androgen action in prostate cancer 总被引:1,自引:0,他引:1
10.
11.
Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer 下载免费PDF全文
Jennifer M Thomas‐Ahner Dayong Wu Xiangtao Liu Zhenqing Ye Liguo Wang Benjamin Sunkel Cassandra Grenade Junsheng Chen Debra L Zynger Pearlly S Yan Jiaoti Huang Kenneth P Nephew Tim H‐M Huang Shili Lin Steven K Clinton Wei Li Victor X Jin Qianben Wang 《The EMBO journal》2015,34(4):502-516
12.
13.
14.
15.
Ras signaling in prostate cancer progression 总被引:7,自引:0,他引:7
16.
17.
18.
19.
Chih-Pin Chuu John M Kokontis Richard A Hiipakka Junichi Fukuchi Hui-Ping Lin Ching-Yu Lin Chiech Huo Liang-Cheng Su 《Journal of biomedical science》2011,18(1):63
Prostate cancer is the most frequently diagnosed non-cutaneous tumor of men in Western countries. While surgery is often successful
for organ-confined prostate cancer, androgen ablation therapy is the primary treatment for metastatic prostate cancer. However,
this therapy is associated with several undesired side-effects, including increased risk of cardiovascular diseases. Shortening
the period of androgen ablation therapy may benefit prostate cancer patients. Intermittent Androgen Deprivation therapy improves
quality of life, reduces toxicity and medical costs, and delays disease progression in some patients. Cell culture and xenograft
studies using androgen receptor (AR)-positive castration-resistant human prostate cancers cells (LNCaP, ARCaP, and PC-3 cells
over-expressing AR) suggest that androgens may suppress the growth of AR-rich prostate cancer cells. Androgens cause growth
inhibition and G1 cell cycle arrest in these cells by regulating c-Myc, Skp2, and p27Kip via AR. Higher dosages of testosterone cause greater growth inhibition of relapsed tumors. Manipulating androgen/AR signaling
may therefore be a potential therapy for AR-positive advanced prostate cancer. 相似文献